JNJ Chart

1 Month

	Date	Diff
	2024-04-23	+0.3 %
The article discusses how institutional investors, such as Rakuten Securities Inc., have increased their stake in Johnson & Johnson (JNJ) stock, leading to its slight upward movement, and also mentions several other hedge funds making changes to their positions in the company, ultimately contributing to the stock's rise. The article discusses how Johnson & Johnson (JNJ) utilizes Veeva Crossix Prime Segments to reach more precise patient populations in targeted campaigns, resulting in a 0.3% increase in the stock. The stock likely went up due to the success in reaching highly-qualified health audiences through digital media campaigns with the help of Veeva Crossix Prime Segments. Johnson & Johnson (JNJ) stock was up by 0.3% last night, and the article discusses various activities related to Microchip Technology Incorporated, such as institutional investments, insider transactions, and analyst ratings, without explicitly explaining the reason behind the increase in JNJ stock.
	2024-04-22	+0.82 %
Summary: Johnson & Johnson's stock (JNJ) increased by 0.82% last night due to the European Commission's approval of CARVYKTI®, a treatment for relapsed and refractory multiple myeloma developed by Janssen-Cilag International N.V., a Johnson & Johnson company, which has the potential to transform the treatment paradigm for patients battling multiple myeloma. Reason for Stock Increase: The stock likely went up due to the positive results from the CARTITUDE-4 study on CARVYKTI®, which demonstrated statistically significant and clinically meaningful improvement in progression-free survival compared to standard treatment regimens, indicating a promising new therapy option for patients with relapsed and refractory multiple myeloma. The Johnson & Johnson (JNJ) stock went up last night by 0.82% due to the overall improvement in stock market performance, stability in the market, and renewed investor confidence in the biotech sector following a challenging period, as highlighted in an article discussing the 10 best performing biotech ETFs in 2024. The article discusses Cardinal Strategic Wealth Guidance decreasing its holdings in Johnson & Johnson (JNJ) by 11.7% and various other institutional investors' activities, with JNJ's stock going up by 0.82% recently. Johnson & Johnson's stock likely went up due to positive quarterly earnings results exceeding analysts' estimates.
	2024-04-19	+1.49 %
The article discusses the performance of high-yield dividend stocks like Johnson & Johnson (JNJ) compared to dividend growth stocks, highlighting that stocks with strong dividend growth history tend to perform better, as seen in a study that analyzed the period between May 2005 and April 2015. Factors contributing to JNJ stock going up could include its consistent dividend growth history and stable performance during periods of high interest rates. Johnson & Johnson (JNJ) stock was up by 1.49% last night, possibly due to positive news, as the World Health Organization is likely to issue a broader warning about contaminated children's cough syrup made by J&J, but stating that tests conducted so far by Kenvue, which owns Benylin after a spin-off from J&J, did not find diethylene glycol, and the company is working with health authorities. The article discusses the recent 1.49% increase in Johnson & Johnson (NYSE: JNJ) stock, attributed to various large investors modifying their holdings in the company, such as Garland Capital Management Inc. and other institutional investors, and positive quarterly earnings results that exceeded analyst expectations, leading to a rise in the company's share price. The rise in Johnson & Johnson stock can be credited to large investors adjusting their holdings in the company, including Garland Capital Management Inc. and other institutional investors, combined with positive quarterly earnings results that surpassed analysts' estimates, leading to an increase in the stock price.
	2024-04-18	+0.67 %
The article discusses a recent Florida jury decision that concluded Johnson & Johnson's baby powder talc product did not cause the ovarian cancer of a woman. Despite this legal victory for J&J, the company still faces over 50,000 lawsuits related to talc exposure and cancer risks, including some cases involving mesothelioma. J&J's stock might have gone up despite legal challenges due to market perceptions, financial outlook, or other factors. The article reports that Johnson & Johnson (NYSE: JNJ) stock increased by 0.67% last night, with institutional investors modifying their holdings, analysts providing various ratings, the company announcing positive earnings results, and a recent increase in dividend, likely leading to the stock going up. The Johnson & Johnson (JNJ) stock went up by 0.67% last night due to the growth in the global anti-hypertensive drug market, which is projected to increase from USD 25 billion in 2023 to USD 50 billion by 2033 at a Compound Annual Growth Rate (CAGR) of 7.18% driven by factors such as the rising prevalence of hypertension worldwide, increased demand for anti-hypertensive drugs, growing awareness about hypertension therapeutic regimes, and initiatives by government and private organizations to address hypertension-related issues.
	2024-04-17	+0.22 %
The article discusses Royalty Pharma plc's dividend approval and payment for the second quarter of 2024, with the stock increasing by 0.22% last night, possibly due to positive investor sentiment following the dividend announcement and the company's involvement in funding and acquiring biopharmaceutical royalties. The article discusses various applications of AI in businesses, highlighting its significance in streamlining processes, risk management, security, product development, sales, customer service, and more, ultimately leading to increased efficiency, reduced costs, and higher profits. Johnson & Johnson's (JNJ) stock went up by 0.22% due to the company's intentions to utilize AI to streamline drug development, accelerate clinical trials, and enhance customer and employee interactions with advanced chatbots. The article primarily discusses Johnson & Johnson's (JNJ) stock, which experienced a 0.22% increase. The stock rose due to various institutional investors, including Sandy Spring Bank and others, either increasing their holdings or purchasing shares of the company. Moreover, JNJ reported positive quarterly earnings results, along with a dividend increase, leading to favorable analyst ratings and price target adjustments for the stock.
	2024-04-16	-2.13 %
Johnson & Johnson (JNJ) stock was -2.13% down, hitting its lowest close since late 2020, despite posting better-than-expected profit for the first quarter, with the dip likely attributed to sales falling slightly short of expectations. Johnson & Johnson (JNJ) stock was down 2.08% last night, possibly due to various market factors affecting the stock market. The article discusses Johnson & Johnson (JNJ) stock, which was down 2.13% last night amidst a positive trend in futures for the Dow Jones Industrial Average, S&P 500, and NASDAQ Composite; the stock's decline was attributed to the company's mixed quarterly results.
	2024-04-15	+0.05 %
The article mentions that the Johnson & Johnson (JNJ) stock was up 0.05% last night, and the reason for its increase could be related to the company's upcoming early Tuesday report along with factors such as Dow Jones futures, S&P 500 futures, Nasdaq futures, and Treasury yields. The article discusses the overall cautiousness in U.S. stock markets due to geopolitical tensions and higher interest rates, but Johnson & Johnson (JNJ) stock went up 0.05% likely due to anticipation surrounding its upcoming quarterly results amidst a weak start to the earnings season for other companies. The article discusses Johnson & Johnson (JNJ) stock, which was slightly up by 0.05% last night, and highlights expectations for the company's Q1 2024 results, attributing the potential uptick in the stock to higher MedTech sales and the performance of key pharmaceutical products like Darzalex, Stelara, and Tremfya.
	2024-04-12	-0.85 %
The article discusses Chemometec A/S's clarification of revenue guidance and lower-than-expected operating profit for the 2023/24 financial year, impacting Johnson & Johnson's stock, which went down by -0.85% as a result. The Johnson & Johnson (JNJ) stock decreased by 0.85% due to a clarification of guidance for revenue and lower than expected operating profit in the 2023/24 financial year.
	2024-04-11	-0.94 %
The article discusses Johnson & Johnson (JNJ) collaborating with Rallybio Corporation (RLYB) to develop therapeutic approaches for FNAIT, a rare immune disorder affecting babies, which caused their stock to decline by 0.94% last night, with potential market factors like overall market conditions, company performance, or investor sentiment leading to the decrease. The article discusses how Johnson & Johnson (JNJ) stock decreased by -0.94% and mentions that Sowell Financial Services LLC decreased its holdings in JNJ shares, contributing to the decline in stock price. Additionally, various other institutional investors and hedge funds have made modifications to their holdings of JNJ stock. The stock has received different ratings from analysts, with conflicting views on its performance. The recent sale of JNJ stock by company insiders is also highlighted. The article discusses that Johnson & Johnson (JNJ) stock was down -0.94% and provides details about institutional investors selling and buying shares of the company, recent insider selling, and information on the company's performance and ratings by analysts. The stock goes down due to various factors including institutional selling, changes in insider holdings, and analyst ratings among others.
	2024-04-10	-1.37 %
The article is about an investigation by Monteverde & Associates PC into Shockwave Medical, Inc. and its proposed sale to Johnson & Johnson, which might have caused a negative investor sentiment leading to the -1.37% decline in Johnson & Johnson (JNJ) stock. Johnson & Johnson (JNJ) stock was down by -1.37% last night; the article mainly discusses Vertex Pharmaceuticals' acquisition of Alpine Immune Sciences for $4.9 billion, which led to a positive outlook for Vertex due to the expansion of its immune treatments pipeline. JNJ's stock may have gone down due to general market fluctuations or specific factors affecting the pharmaceutical industry, but this article does not provide a direct reason for the decrease in JNJ stock value. Representative Lloyd Doggett made investments in various companies, including Johnson & Johnson (JNJ), but JNJ stock went down -1.37% the previous night due to factors not specifically addressed in the given article.
	2024-04-09	+0.46 %
Johnson & Johnson (JNJ) stock was up by 0.46% last night, and the increase in stock value may be attributed to positive news such as strong financial performance, new product developments, successful lawsuits, or other factors contributing to investor confidence in the company. The article discusses Johnson & Johnson (JNJ) stock, which was up by 0.46% last night, and the increase in stock value could be attributed to various factors such as positive company news, market trends, investor sentiment, or financial performance. Johnson & Johnson (JNJ) stock was up 0.46% last night, potentially due to positive market sentiment, financial performance, or other factors supporting the company's stock value.
	2024-04-08	-0.52 %
Summary: Johnson & Johnson (JNJ) stock was down 0.52% last night, potentially influenced by a surge in scams targeting employees around the time of its separation from the company last year. Reason for Johnson & Johnson (JNJ) stock going down: The decline in the stock may be linked to the increase in scams targeting employees during the period of the company's separation from Johnson & Johnson last year. The article provides information regarding Model N (NYSE: MODN) being acquired by Vista Equity Partners in an all-cash transaction, with shareholders set to receive $30.00 per share, resulting in a premium and the company becoming privately held post-acquisition. Johnson & Johnson (JNJ) stock went down last night by -0.52%, likely due to factors specific to JNJ's operations, market conditions, or external events. The article discusses Oakmark Fund's first quarter 2024 investor letter, where Kenvue Inc. (KVUE) was highlighted as the largest standalone consumer health company after splitting from Johnson & Johnson in May 2023, with its stock price closing at $20.25 per share on April 5, 2024; Johnson & Johnson's stock may have gone down due to Kenvue's market share losses and litigation issues affecting its performance.
	2024-04-05	-0.07 %
The article reports that Johnson & Johnson (JNJ) stock was down by 0.07% last night, and the decrease in stock price could be attributed to Buttonwood Financial Advisors Inc. reducing its position in JNJ shares during the 4th quarter, along with other large investors also buying and selling JNJ shares, impacting the stock's performance. The article discusses a market decline that impacted European and UK stock indexes due to hawkish comments from Federal Reserve officials, a spike in Middle East tensions, and hotter-than-expected US jobs data, resulting in Johnson & Johnson (JNJ) stock going down by -0.07%. Summary: The U.S. FDA approved the use of Bristol-Myers Squibb and 2seventybio's cell therapy Abecma in less severely affected patients with blood cancer, while Johnson & Johnson's stock went down last night, possibly due to the FDA also reviewing their cancer cell therapy Carvykti for use in less severely affected patients. Reason for Johnson & Johnson stock going down: The drop in Johnson & Johnson's stock price could be attributed to the news of the FDA's review of their cancer cell therapy Carvykti for use in less severely affected patients, following the approval of a competitor's therapy for similar conditions.
	2024-04-04	-1.14 %
Summary: Johnson & Johnson (JNJ) advises its shareholders to reject a mini-tender offer by TRC Capital Investment Corporation, which aims to purchase up to 1 million shares of JNJ stock at a price lower than the market value, causing JNJ stock to drop by -1.14%. Reason for stock drop: The stock price of Johnson & Johnson (JNJ) went down due to an unsolicited mini-tender offer made by TRC Capital Investment Corporation offering to purchase shares below the current market price, prompting JNJ to advise shareholders against accepting the offer. Summary: Trinity Biotech plc announced their fiscal year 2023 results and business updates, including a comprehensive transformation plan and biosensor technology acquisition progress. Reason for Johnson & Johnson (JNJ) stock going down: The article does not directly explain why Johnson & Johnson stock went down. Johnson & Johnson's stock price could have been affected by general market conditions, sector-specific news, or company-specific factors. Summary: The article discusses a significant milestone achieved by HEALWELL AI's subsidiary Pentavere Research Group in using generative AI to identify rare lung cancer patients, highlighting the application of AI in precision oncology, which also involved industry leaders from Johnson & Johnson. Johnson & Johnson stock went down likely due to general market conditions, industry-specific factors, or news related to the company. Reason for Johnson & Johnson (JNJ) stock going down: The decrease in JNJ stock may have been influenced by general market trends, industry-related news, or specific company developments that impacted investor sentiment.
	2024-04-03	-2.2 %
The Johnson & Johnson (JNJ) stock went down by -2.2% last night due to a major shareholder, Swedbank Robur Fonder AB, decreasing its holding of shares and voting rights to below 5% of the total share capital and voting rights in ChemoMetec A/S, a company connected to Johnson & Johnson. Article Summary: Johnson & Johnson (JNJ) stock was down by 2.2% last night, likely due to a decrease in the holding of shares and voting rights by major shareholder Swedbank Robur Fonder AB in ChemoMetec A/S, a company connected to Johnson & Johnson. Reason for Johnson & Johnson (JNJ) stock going down: The decrease in the holding of shares and voting rights by major shareholder Swedbank Robur Fonder AB in ChemoMetec A/S, a company connected to Johnson & Johnson, likely contributed to the decline in JNJ stock.
	2024-04-02	-0.03 %
The article discusses Nanobiotix's completion of the dose escalation part of a Phase 1 study evaluating NBTXR3 for patients with non-small cell lung cancer. Johnson & Johnson(JNJ) stock may have gone down last night due to factors unrelated to Nanobiotix's announcement, as stock prices can fluctuate for various reasons such as market trends, economic indicators, or company-specific news impacting investor sentiment. Summary: The Biden administration has responded to offers from the manufacturers of 10 high-cost drugs selected for the U.S. Medicare program's pricing negotiations, with Johnson & Johnson being one of the companies involved, but no details were provided. Reason for Johnson & Johnson (JNJ) stock going down: The stock might have experienced a slight decrease due to uncertainties surrounding the pricing negotiations of high-cost drugs with the Biden administration, which could potentially impact JNJ's future revenues and profits.
	2024-04-01	-0.26 %
The article introduces Jeremiah A. Sparks as the new Chief Commercialization Officer of Spectral AI, a company specializing in AI for medical diagnostics in wound care, and highlights the launch of their DeepView system, set to enhance wound treatment decisions. Johnson & Johnson (JNJ) stock went down due to factors unrelated to Spectral AI, such as their revenue decline and negative P/E ratio. The article is about the appointment of Jeremiah A. Sparks as Chief Commercialization Officer at Spectral AI, focusing on medical diagnostics for wound care, with his experience from companies like AVITA Medical, Johnson & Johnson, and others. Johnson & Johnson (JNJ) stock went down last night by -0.26% possibly due to various factors affecting the market such as economic conditions, company performance, or general market trends. Johnson & Johnson (JNJ) stock went down by -0.26% last night, and the article discusses ETFs as a potential investment option, such as the VanEck Vectors Morningstar Wide Moat ETF, Vanguard Australian Shares Index ETF, and Vanguard MSCI Index International Shares ETF, with Johnson & Johnson being among its largest holdings. The reason for JNJ stock decline is not mentioned in the article.
	2024-03-28	+0.15 %
The article discusses key appointments to the board of directors of iLearningEngines following its business combination with Arrowroot Acquisition Corp., with Michael Moe and Ian Davis joining, both having significant business and investment experience. Johnson & Johnson (JNJ) stock went up due to these appointments signaling positive growth opportunities for iLearningEngines. The article discusses Johnson & Johnson (JNJ) stock, which was up 0.15% last night, and attributes this increase to Sawyer & Company Inc reducing its stake in JNJ during the 4th quarter, as well as several other hedge funds and institutional investors modifying their holdings of the stock, alongside various insider transactions and analyst ratings affecting JNJ's stock performance. Johnson & Johnson (JNJ) stock was up by 0.15% last night, and the article highlights the growing presence of Artificial Intelligence (AI) in various industries, emphasizing on the potential benefits and applications of AI, such as accelerating scientific and medical research and improving customer behavior analysis in retailers. The rise in JNJ stock could be attributed to its investment in AI, showcasing the company's willingness to engage in cap-ex spending and adopt AI strategies that could lead to enhanced efficiency and growth in the future.
	2024-03-27	+1.41 %
Summary: Johnson & Johnson (JNJ) stock was up 1.41% last night as Godsey & Gibb Inc. increased its holdings in JNJ, and other hedge funds also added to their stakes, leading to positive investor sentiment and stock price growth. Reason for Stock Increase: JNJ stock rose due to increased holdings by institutional investors like Godsey & Gibb Inc. and positive sentiment from other hedge funds adding to their positions, reflecting optimism in the company's performance and potential for growth. The Johnson & Johnson (JNJ) stock rose by 1.41% last night, and the stock goes up due to investors remaining invested in the market over time, despite market fluctuations, as historically, their returns are higher compared to those who try to time the market by jumping in and out. The article mentions that Johnson & Johnson (JNJ) stock went up by 1.41% last night. The stock might have gone up due to positive market sentiment or news about the company's performance and growth prospects.
	2024-03-26	+0.35 %
The article discusses how Johnson & Johnson's stock (JNJ) rose by 0.35% last night, with insights indicating that various investment consulting firms increased their stakes in the company during the 4th quarter, leading to a positive investor sentiment that contributed to the stock's increase. The article discusses the recent increase in Johnson & Johnson (JNJ) stock, up by 0.35%, with Financiere des Professionnels Fonds d investissement inc. growing its holdings in the company and various other institutional investors and hedge funds adding stakes, while insider trading activities were reported. JNJ's stock likely went up due to increased interest from institutional investors and positive analyst ratings, such as UBS Group raising it to a "buy" rating, and positive quarterly earnings results reported by the company. The article discusses Johnson & Johnson (JNJ) stock, which was up by 0.35% last night. The reason for Johnson & Johnson's stock going up could be due to positive company developments, financial performance, market conditions, or investor sentiment.
	2024-03-25	-0.01 %
The article discusses Oak Harvest Investment Services increasing its position in Johnson & Johnson (JNJ) stock by 5.2% during the 4th quarter and various other hedge funds buying and selling shares of the company, with JNJ stock closing -0.01% down last night; the stock might have decreased due to institutional investors adjusting their positions or market sentiment. The article discusses how Allred Capital Management LLC reduced its holdings in Johnson & Johnson (JNJ) by 0.8% in the fourth quarter, resulting in a -0.01% decrease in the stock price, likely contributing to the drop. The article discusses how CoreCap Advisors LLC reduced its holdings in Johnson & Johnson (JNJ) by 4.5%, leading to a minor 0.01% decline in the stock. The decrease in JNJ stock could be attributed to several large investors, including CoreCap Advisors LLC, reducing their holdings in the company, potentially impacting the stock's performance.
	2024-03-22	-0.33 %
The article discusses how Moody National Bank Trust Division decreased its position in Johnson & Johnson, leading to a 0.33% decrease in the stock. This stock decline may be attributed to institutional investors reducing their stake in the company, including Moody National Bank Trust Division, as mentioned in the article. The article provides an update on Johnson & Johnson (JNJ) stock, which was down by 0.33% last night, citing institutional investor activity and insider selling, with analysts attributing the stock decline to updated price targets and ratings. The article discusses how Shulman DeMeo Asset Management LLC grew its position in Johnson & Johnson (JNJ) by 1.3% during the fourth quarter, but the stock was -0.33% down last night. Johnson & Johnson's stock likely went down due to a combination of factors including market conditions, investor sentiment, and potentially profit-taking by major shareholders like Johnson & Johnson itself and major shareholder & Johnson Johnson.
	2024-03-21	-0.01 %
Summary: Bremer Bank National Association increased its stake in Johnson & Johnson by 1.9% in the fourth quarter, while other hedge funds also made modifications to their holdings. Despite positive earnings results for the quarter, the stock of Johnson & Johnson (JNJ) went down by -0.01%, with potential reasons for this decline possibly being attributed to the actions of institutional investors. Reason for JNJ stock going down: The stock may have gone down due to profit-taking actions or portfolio rebalancing by institutional investors who have increased their stake in the company recently. The article discusses Praetorian Wealth Management Inc. purchasing a new position in Johnson & Johnson stock recently, with several other hedge funds and institutional investors also adjusting their holdings. The stock had declined by -0.01%, and multiple research firms have provided various ratings and price targets for JNJ. Despite recent transactions involving the sale of company shares by insiders, the reason for Johnson & Johnson stock going down is not specifically mentioned in the article. Summary: AEGON ASSET MANAGEMENT UK Plc and other institutional investors have made significant purchases of Johnson & Johnson (JNJ) shares, with AEGON ASSET MANAGEMENT UK Plc acquiring 397,074 shares. Despite these investments, Johnson & Johnson (JNJ) stock went down by -0.01%, and the decrease could be due to various factors such as insider selling or changes in market conditions affecting the stock price. Reason for stock decline: The decline in Johnson & Johnson (JNJ) stock could be attributed to a combination of factors, including insider selling by EVP Jennifer L. Taubert and a major shareholder, as well as changes in market conditions or investor sentiments impacting the stock price.
	2024-03-20	-0.29 %
Summary: Diligent Investors LLC increased its stake in Johnson & Johnson (JNJ) by 2.7% during the fourth quarter, with various other institutional investors also buying and selling shares, while Johnson & Johnson's stock last night was -0.29% down, possibly affected by recent insider selling activities. Reason for stock going down: Johnson & Johnson's stock may have gone down due to various major shareholders and insiders selling off shares, as well as research report rating changes by analysts and a decrease in revenue reported during the last earnings release in January. The article discusses Clarity Wealth Advisors LLC increasing its position in Johnson & Johnson (JNJ) stock and how various other large investors have also bought and sold shares. JNJ stock saw a decrease of 0.29% in value recently, potentially driven by changes in investor positions and market sentiment. Summary: Beech Hill Advisors Inc. reduced its holdings in Johnson & Johnson stock by 9.7% in the 4th quarter, along with other large investors making changes to their positions, resulting in a 0.29% decrease in the stock price recently. Various research reports and ratings have been issued on JNJ stock, while major shareholders have been selling shares, contributing to the overall stock performance. Reason for stock decline: The decrease in Johnson & Johnson stock can be attributed to the recent sell-offs by major shareholders as detailed in the article, along with investors making changes to their positions in the company, leading to a reduction in overall holding percentages and affecting the stock price negatively.
	2024-03-19	-0.35 %
Summary: Nvidia introduced its new Blackwell chips at the GTC conference, impacting its stock positively as investors were impressed by the technology, while Johnson & Johnson's stock declined last night due to other market factors unrelated to the article. Reason for Johnson & Johnson (JNJ) stock going down: Johnson & Johnson's stock experienced a -0.35% decline, likely influenced by factors separate from the Nvidia article, such as broader market trends, company-specific news, or overall economic conditions. The article mentions that Johnson & Johnson (JNJ) stock was down by -0.35% last night, and the reason for the decrease in stock value is not provided in the text. The article discusses the performance of various stocks in the US market, with Johnson & Johnson (JNJ) stock going down by 0.35% and being one of the worst performers, likely due to factors specific to the company or industry influencing its stock price.
	2024-03-18	-0.9 %
Johnson & Johnson (JNJ) stock was down 0.9% last night, possibly due to market factors like overall market performance, economic news, or specific company-related information. The article discusses a major shareholder announcement regarding Invesco Ltd. increasing its holding of voting rights in ChemoMetec A/S above 5%, affecting Johnson & Johnson stock, which went down by 0.9% last night; the stock might have dropped due to the impact of this shareholder announcement on market sentiment. Johnson & Johnson (JNJ) stock was down -0.9% last night after reaching a settlement agreement with Fresenius Kabi and Formycon for a proposed ustekinumab biosimilar to Stelara® in Europe and Canada, impacting the stock price due to undisclosed terms of the settlement and potential implications for JNJ's sales of its Stelara® product.
	2024-03-15	-0.65 %
The article reports that WuXi AppTec left the Biotechnology Innovation Organization due to legislative efforts in the U.S. that were negatively affecting its membership, and as a result, WuXi AppTec's shares went down, leading to Johnson & Johnson's stock to decrease by -0.65%. The Johnson & Johnson (JNJ) stock was down 0.65% last night after advisers to the U.S. Food and Drug Administration voted in favor of allowing the use of J&J's cell therapy as an earlier treatment for a type of blood cancer, which may have caused concerns about the risks and benefits associated with the therapy, impacting the stock price negatively. The article discusses the positive recommendation for CARVYKTI by the FDA's Oncologic Drugs Advisory Committee based on Phase 3 study results, which led to a -0.65% decrease in Johnson & Johnson (JNJ) stock. JNJ stock may have gone down due to potential competition and concerns regarding the safety profile of CARVYKTI, which includes warnings of severe adverse reactions like cytokine release syndrome, neurologic toxicities, and secondary hematological malignancies.
	2024-03-13	-1.01 %
Summary: Chemometec A/S announced the appointment of a new CEO, Martin Helbo Behrens, prompting the resignation of the current CEO, Rasmus Kofoed. Reason for Johnson & Johnson stock going down: The article did not directly mention Johnson & Johnson stock, so it is not clear why it went down. Summary: ChemoMetec A/S has appointed its current COO, Martin Helbo Behrens, as the new CEO, and the stock of Johnson & Johnson (JNJ) went down by -1.01% last night. Reason for JNJ Stock Decline: The decline in Johnson & Johnson (JNJ) stock was likely due to factors specific to the company itself, and not directly related to the appointment of a new CEO at ChemoMetec A/S. Johnson & Johnson (JNJ) stock fell by -1.01% last night, and the reason for the decline was not mentioned in the provided article, which is about the appointment of a new CEO at ChemoMetec.
	2024-03-11	+1.07 %
The article discusses a major shareholder announcement related to ChemoMetec A/S by BlackRock, Inc., indicating an increase in shareholding to 12.17%; however, this information is unrelated to Johnson & Johnson (JNJ) stock performance. JNJ stock went up by 1.07% last night primarily due to positive market sentiments, company performance, overall industry trends, or other external factors influencing investor confidence. "Johnson & Johnson (JNJ) stock rose by 1.07% last night after submitting a supplement biologics license application for their treatment tremfya, which showed significant improvements in symptoms and disease activity in adults with ulcerative colitis." The stock likely went up due to the positive results and potential approval of tremfya for a new indication. The article is about Johnson & Johnson (JNJ) stock increasing by 1.07% last night, and the reason for the stock surge might be due to positive market sentiment or specific news related to the company.
	2024-03-07	-0.29 %
The article reports that Johnson & Johnson (JNJ) stock was -0.29% down, as high levels of the carcinogen benzene were found in various acne products from different brands, leading to concerns and potential recalls. The article discusses changes in Best Buy Co., Inc.'s board leadership, with J. Patrick Doyle retiring as Board Chairman and David Kenny succeeding him, effective June 12, 2024. Additionally, Eugene A. Woods will also retire from the board. The reason for Johnson & Johnson (JNJ) stock going down is not directly addressed in the article. The article discusses Kenvue Inc.'s presentation at the American Academy of Dermatology (AAD) meeting showcasing studies on the effectiveness of Neutrogena® and Aveeno® products in skincare, such as moisturizing, skin barrier improvement, sun damage protection, and acne reduction, which attracted positive feedback from consumers and experts. This positive news on their skincare brands may not have directly influenced the stock price, but external factors such as market conditions or investor sentiments could have contributed to Johnson & Johnson (JNJ) stock going down by -0.29%.
	2024-03-06	-0.39 %
The article reports that high levels of cancer-causing benzene were found in acne treatment products from various brands like Estee Lauder, Target, and Reckitt Benckiser-owned Clearasil by independent U.S. laboratory Valisure, leading to a 3% drop in Estee Lauder shares, and similar previous recalls in products from companies like Johnson & Johnson due to contaminated ingredients causing benzene impurities. This discovery of benzene directly in benzoyl peroxide itself in acne treatment products is a new concern leading to potential stock declines for affected companies like Johnson & Johnson.
	2024-03-05	+0.08 %
The article primarily discusses the quality and importance of sunscreen products in skincare, highlighting their significance in protecting against sun damage and skin cancer. Johnson & Johnson (JNJ) stock rose by 0.08%, potentially due to their involvement in the sun care industry through their brands like Neutrogena and innovative products, demonstrating their commitment to skin health and offering multifunctional solutions like the Bright Boost Moisturizer with Broad Spectrum SPF 30. The article discusses proposed new board members at Sandoz, impacting changes in leadership, such as Remco Steenbergen becoming the new CFO, leading to investor optimism and a 0.08% increase in Johnson & Johnson (JNJ) stock due to increased confidence in the company's strategic direction.
	2024-03-01	+0.46 %
Summary: The article discusses the stock market updates for March 1, 2024, highlighting that Johnson & Johnson (JNJ) stock saw a rise of 0.46% last night due to broader market trends. Reason for Johnson & Johnson stock rise: It can be attributed to the positive overall market sentiment driven by the strong GDP numbers released, showing a robust 8.4% growth in Q3 FY24, which surpassed analysts' expectations. The U.S. health regulator approved Johnson & Johnson's therapy in combination with other chemotherapies for the first-line treatment of a type of lung cancer, leading to a 0.46% increase in JNJ stock, likely due to the positive outlook for the company's new treatment and FDA approvals. Mersana Therapeutics (NASDAQ: MRSN) has showcased progress in antibody-drug conjugate (ADC) development with improvements in efficacy and financial stability, leading to a surge in stock performance; Mersana's strategic initiatives and strong cash position have contributed to investor confidence and the company's growth trajectory.
	2024-02-29	-0.11 %
The article announces the appointment of Kevin Hourican and David Elkins to Tapestry, Inc.'s Board of Directors, but does not specifically mention why Johnson & Johnson (JNJ) stock went down by -0.11%.
	2024-02-28	+0.35 %
The article provides an overview of biotech stocks and the healthcare industry, detailing the potential benefits and risks of investing in companies focused on biotechnology and pharmaceuticals. It explains that Johnson & Johnson's stock went up 0.35% last night, likely driven by the company's innovative treatments, strategic acquisitions, and ongoing investments in health innovation, making it a pivotal player in the healthcare industry alongside other key players such as Eli Lilly, Novo Nordisk, UnitedHealth Group, Merck, AbbVie, Thermo Fisher Scientific, Roche Holding, and Novartis. The Johnson & Johnson (JNJ) stock went up by 0.35% after concerns on the affordability of healthcare in the U.S. were raised by Senator Bernie Sanders, who led a Senate hearing pressing pharmaceutical CEOs on drug pricing, suggesting that the companies are prioritizing profits over making medicines more affordable for patients. The article discusses the rise of Johnson & Johnson (JNJ) stock by 0.35% last night, and one factor that could contribute to its increase is the advancement of immersive digital experiences such as Apple's Vision Pro that allow brands like Johnson & Johnson to develop native app experiences and engage with consumers more thoughtfully.
	2024-02-26	-0.65 %
Summary: Amazon will replace Walgreens in the Dow Jones Industrial Average, leading to a reshuffling of the stock index due to Walmart's 3-for-1 stock split, with Johnson & Johnson being part of the Dow and remaining among the 30 companies. Reason for Johnson & Johnson's stock going down: The article does not provide specific information about Johnson & Johnson's stock going down; however, generally, stock movements can be influenced by various factors such as overall market conditions, company-specific news, economic indicators, and investor sentiment. The article discusses how Profund Advisors LLC reduced its position in Johnson & Johnson stock, leading to a 0.65% decrease in the stock price. Johnson & Johnson (JNJ) stock went down possibly due to several institutional investors and hedge funds, including Profund Advisors LLC, making changes to their positions in the company, which impacted the stock's performance negatively. Summary: Peloton Wealth Strategists increased its holdings in Johnson & Johnson by 2.2% in the 3rd quarter, but last night the stock declined by 0.65%. Several other hedge funds and institutional investors also acquired or sold shares of JNJ. Reason for stock decline: The decrease in Johnson & Johnson's stock could be attributed to various factors such as profit-taking by investors, market conditions, or any negative news impacting the company's performance.
	2024-02-23	+0.87 %
The article discusses Aigen Investment Management LP's new position in Johnson & Johnson (JNJ) stock, as well as other institutional investors changing their positions, leading to a 0.87% increase in the stock value, attributed to positive analyst reports, including upgrades and boosted price targets, along with the company's strong quarterly earnings results and dividend declaration. The summary of the article is that Johnson & Johnson (JNJ) stock was up by 0.87% last night, possibly due to actions such as Peachtree Investment Partners LLC lowering its stake in JNJ, various institutional investors and hedge funds buying shares, an insider selling shares, and several analysts issuing positive reports on the stock. Summary: CI Investments Inc. reduced its stake in Johnson & Johnson (JNJ) by 19.3% during the 3rd quarter, leading to a 0.87% increase in the stock. The stock went up due to various institutional investors either adding to or reducing their stakes in the company. Reason for stock increase: The increase in Johnson & Johnson (JNJ) stock was due to various institutional investors adjusting their stakes in the company, such as CI Investments Inc., State Street Corp, Moneta Group Investment Advisors LLC, Geode Capital Management LLC, Morgan Stanley, and Capital International Investors.
	2024-02-22	+1.12 %
Summary: Last night, Johnson & Johnson (JNJ) stock was up by 1.12%, and the reason for this increase could be attributed to various factors such as positive news about the company, strong financial performance, market conditions, or investor sentiment. Why Johnson & Johnson (JNJ) stock goes up: The stock may have gone up due to positive news about the company, strong financial performance, market conditions, or investor sentiment. The article discusses Model N, Inc. (NYSE: MODN) and its cloud revenue management solutions, mentioning that Johnson & Johnson (JNJ) stock was up by 1.12% last night, possibly due to positive news or market conditions impacting the pharmaceutical sector.
	2024-02-21	+0.52 %
The article discusses the performance of dividend kings, including Johnson & Johnson (JNJ) stock. Despite last night's 0.52% increase in JNJ stock, the article highlights that being a dividend king may not always result in superior performance compared to the market index, with some companies striving to maintain their streak of dividend increases at the expense of other strategic investments like research and development, new factories, or stock buybacks. The study showed that out of the seven leading dividend king stocks analyzed, only one beat the index in 2023. Johnson & Johnson's stock may have gone up due to factors such as its relatively low valuation and solid performance as a healthcare giant. The article discusses LivaNova PLC's financial results for the quarter and full year ended December 31, 2023, with revenue growth and an increase in adjusted earnings per share reported. Johnson & Johnson (JNJ) stock went up 0.52% likely due to improvement in revenue growth across all segments, an increase in adjusted operating margin, and a rise in adjusted diluted earnings per share for both the fourth quarter and full year 2023.
	2024-02-20	+0.84 %
Johnson & Johnson (JNJ) stock was up 0.84% last night after the U.S. Food and Drug Administration approved its application for Tecvayli, a supplemental biologics license application allowing for reduced dosing frequency, particularly benefiting patients with relapsed or refractory multiple myeloma who have achieved and maintained a complete response or better for at least six months. Johnson & Johnson (JNJ) stock was up 0.84% last night, and the stock went up partly due to actions taken by institutional investors, such as Heritage Investors Management Corp reducing its holdings in the company and various other hedge funds adding to or reducing their stakes, as well as positive ratings and price target upgrades by research firms. Johnson & Johnson (JNJ) stock was up by 0.84% last night following the approval of a bi-weekly dose of the blood cancer therapy Tecvayli by the U.S. Food and Drug Administration, and the end of the patent for its flagship drug by January 23, 2024, according to J&J's CFO Joseph Wolk. The stock likely went up due to positive news related to drug approvals and the company's patent status.
	2024-02-16	-0.87 %
The article discusses how pharmaceutical companies like Johnson & Johnson are facing criticism for high drug prices in the United States compared to other nations, leading to a push for nationwide regulation on all drug prices. The recent decline in Johnson & Johnson's stock may be attributed to the ongoing debate and potential regulations on drug prices. The article discusses Johnson & Johnson (JNJ) as a long-term investment with potential for growth and income, mentioning that the stock has seen significant gains over the years. However, it does not provide any information on why the stock went down by 0.87% recently.
	2024-02-15	+1.4 %
The article discusses the recent increase in Johnson & Johnson (JNJ) stock by 1.4%, and attributes it to hedge funds adding or reducing their stakes in the company, as well as positive analyst ratings. The article discusses how Johnson & Johnson's stock went up 1.4% last night, possibly due to Platform Technology Partners increasing its stake in the company during the third quarter. Other hedge funds and institutional investors have also modified their holdings of Johnson & Johnson, contributing to the stock's rise. The article discusses an increase in Johnson & Johnson (JNJ) stock by 1.4%. The stock went up due to Pine Valley Investments Ltd Liability Co increasing its stake in the company, as well as other hedge funds adding or reducing their stakes.
	2024-02-14	-0.47 %
The article announces that Johnson & Johnson will be participating in a healthcare conference, and provides information on how to access the webcast. The reason for the stock going down is not mentioned in the article.
	2024-02-13	-0.87 %
Johnson & Johnson (JNJ) stock went down by 0.87% last night, and the reason for this decline is not mentioned in the article.
	2024-02-12	+0.7 %
Johnson & Johnson (JNJ) stock went up by 0.7% last night, however, the article does not provide any information or explanation as to why the stock experienced the increase. Johnson & Johnson (JNJ) stock went up 0.7% last night, and the reason for the increase is not mentioned in the article. The article is about Kuehn Law investigating potential claims related to proposed mergers involving companies like Johnson & Johnson. The Johnson & Johnson stock went up by 0.7% last night, and the reason for the increase is not mentioned in the article.
	2024-02-09	+0.23 %
Johnson & Johnson (JNJ) stock went up 0.23% last night, and the reason for the increase is not provided in the article. The article discusses various topics including retirement finances, stock market indicators, dividend-paying stocks, pharmaceutical companies, and the performance of the U.S. stock market. The reason why Johnson & Johnson's stock went up is not mentioned in the article.
	2024-02-08	-1 %
Johnson & Johnson's stock (JNJ) went down by 1.0% after its consumer-health business, Kenvue Inc., reported lower-than-expected revenue for the fourth quarter and gave soft guidance for 2024 due to softer performance in the U.S. skin health and beauty business and continued softness in China. The Johnson & Johnson (JNJ) stock was down 1.0% last night. The stock decline can potentially be attributed to Kenvue Inc., a consumer-health business spun out from Johnson & Johnson, missing revenue estimates for the fourth quarter and offering weak guidance for 2024. Johnson & Johnson (JNJ) stock went down by -1.0% last night following a Senate hearing where pharmaceutical executives, including the CEO of Johnson & Johnson, declined to commit to lowering U.S. prices to match those in other countries like Canada. The executives blamed higher prices on pharmacy benefit managers (PBMs) and Senator Bernie Sanders criticized the companies for prioritizing profits over research and development.
	2024-02-07	-0.05 %
Johnson & Johnson (JNJ) stock went down by -0.05% due to changes in positions by institutional investors and hedge funds. Johnson & Johnson (JNJ) stock went down by -0.05% last night, and the reason for the decline is not mentioned in the article. Johnson & Johnson (JNJ) stock went down by 0.05% due to abrdn plc cutting its position in the company by 12.1% during the third quarter, along with other large investors modifying their holdings in the company.
	2024-02-06	+1.45 %
Johnson & Johnson's stock (JNJ) was up 1.45% last night, but the article does not provide a specific reason for the increase. Johnson & Johnson (JNJ) stock went up by 1.45% due to increased investments from Callan Capital LLC and other institutional investors and hedge funds, as well as positive earnings results and the announcement of a quarterly dividend. The article reports that Johnson & Johnson's stock (JNJ) increased by 1.45% last night, but it does not provide a specific reason for the increase.
	2024-02-05	-0.52 %
Last night, Johnson & Johnson (JNJ) stock went down by 0.52%, possibly due to Aldebaran Financial Inc. reducing its stake in the company by 7.3% in the third quarter, according to the company's recent filing with the Securities & Exchange Commission. Johnson & Johnson (JNJ) stock went down by 0.52% due to a decrease in stake by institutional investor Ifrah Financial Services Inc. and a downgrade in rating by Wells Fargo & Company. The article discusses the success of Global Blood Therapeutics (GBT) in developing a drug to treat sickle cell disease, which led to its acquisition by Pfizer. Dr. Ted Love, the former CEO of GBT, shares his journey and the challenges faced in developing the drug. The stock of Johnson & Johnson (JNJ) went down, but the article does not provide a specific reason for this decrease.
	2024-02-02	-1.11 %
Johnson & Johnson (JNJ) stock went down 1.11% last night due to decreased holdings by Nomura Asset Management Co. Ltd. and other institutional investors. Johnson & Johnson (JNJ) stock was down 1.11% last night, and the decline can be attributed to various factors including the selling of shares by institutional investors and the downgrade of the stock by research analysts. The article reports that Johnson & Johnson (JNJ) stock went down by 1.11% due to Carl P. Sherr & Co. LLC reducing its holdings in the company's stock, while other institutional investors and hedge funds also reduced their stakes.
	2024-02-01	-0.34 %
Johnson & Johnson (JNJ) stock went down by -0.34% last night, but the article does not provide a specific reason for the decrease in stock price.
	2024-01-31	+0.08 %
Johnson & Johnson (JNJ) stock went up last night by 0.08%, but the article does not explain why it specifically went up. Johnson & Johnson (JNJ) stock was up 0.08% last night, and it may be attributed to institutional investors modifying their holdings of JNJ and positive quarterly earnings results. The article discusses how JNBA Financial Advisors reduced its stake in Johnson & Johnson (JNJ) by 1.3% during the third quarter, while other large investors bought and sold shares of the company, and provides ratings and price targets from research analysts. The reason for Johnson & Johnson's stock going up is not explicitly mentioned in the article.
	2024-01-30	-0.37 %
The article discusses how 2seventy bio, Inc. (Nasdaq: TSVT) is refocusing its business exclusively on the commercialization and development of Abecma (idecabtagene vicleucel), a BCMA-targeted CAR T therapy for multiple myeloma, which has led to annual cost savings and an extended cash runway; the stock of Johnson & Johnson (JNJ) may have gone down as a result of this strategic shift. Johnson & Johnson (JNJ) stock went down by -0.37% due to StockNews.com cutting its rating from strong-buy to buy, as well as several other brokerages downgrading their ratings and reducing price targets on the stock. Johnson & Johnson (JNJ) stock went down by 0.37% after the company issued an update on its FY 2024 earnings guidance, providing lower earnings per share and revenue estimates compared to analysts' expectations.
	2024-01-29	-0.09 %
Yacktman Asset Management LP, an institutional investor, reduced its stake in Johnson & Johnson (JNJ) by 23.9%, which may have contributed to the stock's decline; however, the article does not provide a specific reason for the decrease. Johnson & Johnson (JNJ) stock went down by 0.09% due to Martin Investment Management LLC reducing its holdings in the company. Johnson & Johnson (JNJ) stock went down by -0.09% last night, possibly due to Calton & Associates Inc. trimming its holdings in the company by 43.6% in the third quarter, as reported in their recent filing with the Securities and Exchange Commission (SEC).
	2024-01-26	-0.04 %
IRON Financial LLC decreased its stake in Johnson & Johnson (JNJ) by 44.7% in the 3rd quarter, which may have contributed to the slight decrease in the stock price, though other large investors have recently bought shares of JNJ. The article discusses the recent performance of Johnson & Johnson (JNJ) stock, which experienced a slight decline of 0.04% overnight. The reason for the decline is not mentioned in the article. The chief executives of Johnson & Johnson, Merck & Co., and Bristol Myers Squibb will testify before a U.S. Senate committee regarding prescription drug prices, after Senator Bernie Sanders announced that the committee would vote to subpoena them if necessary. The hearing aims to address the high cost of prescription drugs in the United States.
	2024-01-25	+0.38 %
Johnson & Johnson (JNJ) stock went up by 0.38% and acquired new positions from various investors, leading to positive ratings and increased price targets by analysts. Analysts predict strong earnings for the company this year, and it recently announced a quarterly dividend. Investors are optimistic about Johnson & Johnson's products in the healthcare field. The article is not about Johnson & Johnson stock going up, but rather about Kuehn Law, PLLC investigating potential claims related to proposed mergers involving various companies, including Johnson & Johnson's acquisition of Ambrx Biopharma, Inc. The reason for the increase in Johnson & Johnson stock is not mentioned in the article. Johnson & Johnson (NYSE:JNJ) stock went up by 0.38% last night, possibly due to increased positions held by institutional investors such as Stableford Capital II LLC.
	2024-01-24	-0.53 %
The article does not provide information on why Johnson & Johnson (JNJ) stock went down. The article is not about Johnson & Johnson (JNJ) stock going down; it is about Virtualware, a European virtual reality company, reporting record total revenues in 2023. There is no information provided in the article about why Johnson & Johnson stock goes down. Johnson & Johnson (JNJ) stock was down 0.53% last night, and the decrease in stock price can be attributed to lower revenue and earnings per share that missed analyst estimates.
	2024-01-23	-1.64 %
The article discusses how Johnson & Johnson's stock went down by 1.64% and suggests that there is no clear catalyst for an increase in stock price, citing challenges and headwinds that may prevent it from moving higher in the near future. Johnson & Johnson (JNJ) stock went down by 1.64% due to disappointing earnings from other sectors, such as 3M, which came in below Wall Street's expectations. Johnson & Johnson (JNJ) stock went down by -1.64% despite posting strong earnings for the fourth quarter, with sales and adjusted earnings exceeding expectations. The stock decline may be attributed to weakness in certain cancer drugs and an ongoing talcum powder lawsuit settlement, which is expected to cost around $700 million.
	2024-01-22	+0.49 %
Johnson & Johnson (JNJ) stock increased by 0.49% last night as Carmel Capital Partners LLC grew its stake in the company by 22.0% during the third quarter, boosting investor confidence in the stock's performance. Patten & Patten Inc. TN decreased its holdings in Johnson & Johnson (JNJ) stock by 0.8% in the third quarter, which caused the stock to increase by 0.49%. The Johnson & Johnson (JNJ) stock went up by 0.49% last night, and the reason for the increase is not mentioned in the article.
	2024-01-19	+0.29 %
The article discusses Royalty Pharma's announcement of a dividend increase and does not provide information on why Johnson & Johnson's stock went up. Johnson & Johnson (JNJ) stock went up by 0.29% last night due to positive market sentiment and expectations for upcoming earnings reports. Johnson & Johnson (JNJ) stock was up 0.29% last night, and the reason for the increase is not mentioned in the article. The article focuses on U.S. Sen. Bernie Sanders announcing that the Senate Committee on Health, Education, Labor, and Pensions will vote on subpoenas to force two pharmaceutical CEOs, including Johnson & Johnson CEO Joaquin Duato, to explain why their companies charge higher prices for medicine in the U.S. compared to other countries. Sanders argues that it is time to hold pharmaceutical companies accountable for charging high prices and calls for congressional oversight. Consumer advocates welcome the prospect of subpoenas as a means of holding pharmaceutical companies accountable for their pricing practices.
	2024-01-18	+0.49 %
Johnson & Johnson (JNJ) stock went up by 0.49% last night, and the article discusses how the CEOs of Merck and Johnson & Johnson have been subpoenaed to testify before a Senate Committee on high drug prices, with a report revealing that the companies spent more on stock buybacks, dividends, and executive compensation than on research and development, prompting calls for accountability and negotiations on drug prices.
	2024-01-17	-0.06 %
Johnson & Johnson's stock went down by 0.06% recently, potentially due to the company's acquisition of cancer drug developer Ambrx Biopharma for $2 billion and their anticipation of a future surge in cancers. The article discusses an investigation being conducted by Kuehn Law, PLLC into potential shareholder claims related to several proposed mergers, including Johnson & Johnson's acquisition of Ambrx Biopharma. The reason for Johnson & Johnson's stock going down is not mentioned in the article. The article discusses Halper Sadeh LLC's investigation into potential violations of federal securities laws and breaches of fiduciary duties by various companies, including Johnson & Johnson (JNJ). The reason for Johnson & Johnson's stock going down is not mentioned in the article.
	2024-01-16	-1.15 %
Johnson & Johnson (JNJ) stock went down by -1.15% last night, but the article does not provide any specific reasons for the decrease. The article is about investor rights law firm Halper Sadeh LLC investigating several companies, including Johnson & Johnson, for potential violations of securities laws and breaches of fiduciary duties. It does not provide a specific reason for why Johnson & Johnson's stock went down.
	2024-01-12	+0.77 %
The article discusses Apple's board of directors reshuffle and the addition of Dr. Wanda Austin to the board, while Al Gore and James Bell retire. The reason for the stock increase is not mentioned in the article. The Johnson & Johnson (JNJ) stock went up by 0.77% last night, but the article does not provide an explanation for the increase.
	2024-01-11	-0.44 %
The article discusses how Swiss drugmaker Novartis has backed away from pursuing a deal with Cytokinetics, causing the U.S. drug developer's shares to drop over 21%. The reason for the breakdown in talks is unknown at this time. The article discusses the Dogs of the Dow strategy, which involves buying the 10 highest-yielding stocks in the Dow Jones industrial average at the beginning of each year. Last year, Johnson & Johnson (JNJ) replaced Intel on the list, and the stock went down by -0.44%. The decline in Johnson & Johnson's stock can be attributed to various factors and market conditions, which are not specified in the article. Johnson & Johnson (JNJ) stock went down by -0.44% last night due to the breakdown in talks between Swiss drugmaker Novartis and U.S. drug developer Cytokinetics, causing uncertainty about a potential acquisition.
	2024-01-10	+0.15 %
The article discusses how Johnson & Johnson (JNJ) stock went up by 0.15% and attributes the increase in stock to confidence in consumer spending and the company's momentum in digital payment methods. The article states that Johnson & Johnson (JNJ) stock was up 0.15% last night, and it does not provide an explanation for why the stock went up.
	2024-01-09	+0.06 %
Johnson & Johnson (JNJ) stock went up by 0.06% last night, possibly due to the projected increase in the number of Americans aged 65 and older, which is expected to lead to a rise in cancer cases and an increase in the demand for cancer drugs. Johnson & Johnson's stock went up due to its acquisition of Ambrx Biopharma at a significant premium, highlighting the potential for high returns in the biotech sector through strategic mergers and acquisitions.
	2024-01-08	+0.25 %
Johnson & Johnson stock went up because the company has tentatively agreed to pay approximately $700 million to settle an investigation by over 40 US states regarding claims that it wrongfully marketed its talc-based baby powder without warning about potential health risks. This settlement would prevent potential lawsuits alleging that the company hid any links between the talc in its powder and various cancers. Johnson & Johnson's stock went up by 0.25% last night after the announcement of its merger with Ambrx Biopharma, which is expected to be completed in the first half of 2024. The merger involves Johnson & Johnson giving Ambrx Biopharma $2.00 billion in cash in exchange for AMAM stock, and this news contributed to the increase in the stock price. Johnson & Johnson (JNJ) stock went up by 0.25% due to the announcement of their plans to buy cancer therapy developers at a major U.S. healthcare conference, signaling a strong start for mergers and acquisitions in 2024 as the industry seeks to replace revenue from older drugs with promising new ones.
	2024-01-05	+0.31 %
The article announces the appointment of Adam Laponis as chief financial officer of Twist Bioscience Corporation, a company specializing in synthetic DNA, and provides information about his previous experience. There is no information in the article about Johnson & Johnson (JNJ) stock going up.
	2024-01-04	-0.21 %
The article announces that AtriCure, Inc. has appointed Shlomi Nachman, a former Company Group Chairman at Johnson & Johnson, to its Board of Directors, and it does not provide any information or explanation as to why Johnson & Johnson's stock went down. The article discusses the decline in Johnson & Johnson's stock, which went down by 0.21% last night. The reason for the stock's decline is not mentioned in the article.
	2024-01-03	+0.63 %
Johnson & Johnson (JNJ) stock went up by 0.63% last night, likely due to its highest close since September 21. The article discusses the performance of the stock market on the first trading day of the year and speculates on whether the recent downturn is temporary or indicative of a larger decline. Johnson & Johnson's stock went up 0.63% and contributed to the Dow Jones' record-setting gain, while tech stocks like Apple faced a decline due to a change in recommendation by Barclays. The overall market is awaiting the publication of the minutes from the latest US central bank meeting. No specific reason is given for Johnson & Johnson's stock increase. The article discusses the performance of Johnson & Johnson (JNJ) stock, which was up 0.63% last night. The reason for the increase in the stock price is not provided in the article.
	2024-01-02	+2.06 %
Johnson & Johnson (JNJ) stock went up by 2.06% last night, and this increase may be attributed to the announcement that the company's Board of Directors has declared a cash dividend for the first quarter of 2024. Johnson & Johnson (JNJ) stock went up 2.06% last night, potentially due to the Dow remaining in positive territory as defensive stocks like Johnson & Johnson strengthened. Johnson & Johnson (JNJ) stock went up by 2.06% last night, potentially due to the company being categorized as a value stock in the healthcare sector, which has performed better due to restricted access to financing, monetary tightening, and fears of a global recession affecting growth stocks.
	2023-12-29	+0.1 %
Johnson & Johnson (JNJ) stock went up 0.1% after a federal judge allowed shareholders to pursue a class action lawsuit accusing the company of fraudulently concealing asbestos contamination in its talc products, which has led to multiple stock price drops and ongoing mass tort litigation. Johnson & Johnson (JNJ) shareholders are allowed to pursue a class-action lawsuit accusing the company of fraudulently hiding the contamination of its talc products by cancer-causing asbestos, according to a federal judge, which may have caused the stock to go up.
	2023-12-28	+0.15 %
Johnson & Johnson (JNJ) stock went up recently, possibly due to its position as one of the world's largest and most diversified healthcare companies, benefiting from an aging global population and rising standards of living in emerging economies.
	2023-12-27	+0.13 %
The article announces that Avalo Therapeutics is implementing a reverse stock split of their common stock in order to regain compliance with the listing requirements of the Nasdaq Capital Market, which has caused the stock price of Johnson & Johnson (JNJ) to go up by 0.13%. The article discusses the predictions for the Bank of Canada's interest rate changes in 2024 and how it will impact mortgages and investments. The author believes that falling interest rates will benefit certain sectors, such as real estate investment trusts and utilities. In terms of stocks, names like Johnson & Johnson are expected to see some strength and recovery. Overall, the investment world is shifting again, with falling overnight rates being the theme of the year. Johnson & Johnson (JNJ) stock rose by 0.13% last night, and the reason behind this increase was not mentioned in the article.
	2023-12-26	+0.44 %
The article discusses the rise in Johnson & Johnson's (JNJ) stock, which was up by 0.44% last night. The reason for the increase is not mentioned in the article.
	2023-12-22	+0.4 %
The article discusses the rise in Johnson & Johnson (JNJ) stock by 0.4% and speculates that it may be due to the potential impact of inflation laws on innovation. Johnson & Johnson (JNJ) stock increased by 0.4% last night due to positive market sentiment and potential future innovation despite concerns about inflation.
	2023-12-21	+1.02 %
The article is not about Johnson & Johnson (JNJ) stock going up, but rather about the career and net worth of television host Don Lemon. The reason for Johnson & Johnson (JNJ) stock going up is not mentioned in the article. Johnson & Johnson stock (JNJ) went up by 1.02% last night. The stock increase may be attributed to the asset purchase agreement between Janssen Pharmaceuticals Inc, a Johnson & Johnson company, and MeiraGTx Holdings plc for the remaining interests in botaretigene sparoparvovec (bota-vec), a treatment for X-linked retinitis pigmentosa (XLRP).
	2023-12-20	-2.04 %
Johnson & Johnson (JNJ) stock went down by 2.04% because sales of over-the-counter medications for upper respiratory infections have spiked during the pandemic, leading to increased revenue for companies like JNJ in the short term but raising concerns about the overuse and potential side effects of these medications. Johnson & Johnson's (JNJ) stock went down by 2.04% because demand for weight loss drugs and other treatments surged, causing a shift in focus away from Covid vaccines and treatments, and a new policy on Medicare drug price negotiations could eat into revenue and profits for pharmaceutical companies. The article announces that Martin Glensbjerg, COO and deputy chairman of the board at ChemoMetec, will be stepping down and taking on a new role as Senior Advisor, which may have contributed to the -2.04% decrease in Johnson & Johnson's stock.
	2023-12-19	+0.66 %
The article discusses the performance of Johnson & Johnson (JNJ) stock, which was up 0.66% last night. The reason for the stock's increase is not mentioned in the article. The article discusses the resignation of Kim Tyler as President and CEO of Stratabound Minerals Corp., with Wendy T. Chan appointed as the interim CEO, who brings strategic expertise to maximize the value of the company's assets; however, the article does not explain why Johnson & Johnson (JNJ) stock went up. Johnson & Johnson's stock went up because they entered into a commercialization partnership with Mendaera, a company developing technology for medical robotics, to bring Butterfly Network's Ultrasound-on-Chip™ to the robotic intervention market, with revenue anticipated from every unit sold.
	2023-12-18	+0.18 %
The article is about BioSig Technologies, Inc. (NASDAQ: BSGM), a medical technology company that focuses on decoding the body's electrical signals, particularly heart rhythms. They have developed a product called the PURE EP™ Platform, which removes unnecessary distractions and noise from cardiac signals, providing clear actionable insights for arrhythmia treatment. The company has seen success and collaboration with well-respected healthcare institutions and has a strong management team. Johnson & Johnson stock goes up because it is mentioned as one of the leading medical centers that BioSig Technologies collaborates with.
	2023-12-15	-1.09 %
The article discusses Pfizer's net worth, market cap, and market value, highlighting its financial position and market standing. It mentions that Pfizer experienced a significant decrease in market cap in 2023, attributing it to factors such as changes in financial performance, industry trends, and market conditions. It also compares Pfizer's market cap to that of its competitor, Johnson & Johnson, and discusses Pfizer's stock performance, earnings, revenue, and annual reports as important indicators for evaluating the company's financial health and stock value. The article provides information on Procter & Gamble's market capitalization, stock performance, financial performance, growth strategies, and insights from analysts. It does not mention why Johnson & Johnson's stock went down. The article discusses the sectors that make up the S&P 500 stock market index and their importance in analyzing and investing in different industries. It explains that Johnson & Johnson (JNJ), which falls under the healthcare sector, saw a decrease in its stock price, but no specific reason is mentioned for the decline.
	2023-12-14	+0.69 %
BOSTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Johnson & Johnson (JNJ) stock went up by 0.69% last night, likely due to positive market sentiment or other factors not mentioned in the article. The article does not provide any information about Johnson & Johnson's stock going up.
	2023-12-13	+0.46 %
Johnson & Johnson (JNJ) stock went up by 0.46% last night, and the reason for the increase is not mentioned in the article. The article discusses how Johnson & Johnson's stock increased by 0.46% and suggests that the increase may be due to the company's innovative approach despite potential challenges from new inflation laws. Wells Fargo downgraded Johnson & Johnson (JNJ) stock and lowered its price target due to concerns about the loss of exclusivity for the company's product Stelara. Analysts expect this loss of exclusivity to impact earnings growth in the next few years, which may explain the stock's recent decrease.
	2023-12-12	+0.01 %
Johnson & Johnson (JNJ) stock went up by 0.01% last night due to a favorable trading session for the stock market overall, with the S&P 500 and Dow Jones Industrial Average also rising, and trading volume remained lower than its 50-day average volume. Johnson & Johnson (JNJ) stock went up by 0.01% after RB Global announced the appointment of Eric J. Guerin as Chief Financial Officer, effective January 15, 2024, which was seen as a positive move for the company. The article is not about Johnson & Johnson (JNJ) stock going up, but rather about how to gift stocks to someone and the benefits and considerations of doing so.
	2023-12-11	+0.41 %
In a collaboration agreement, MustGrow Biologics Corp. (TSXV: MGRO) announced a partnership with Bayer AG (FSE: BAYN) to commercialize MustGrow's mustard-based biocontrol technologies in Europe, the Middle East, and Africa, excluding certain applications. The deal includes upfront and milestone payments, royalties, and manufacturing sales, and is expected to be worth around $35 to $40 million over the next few years. The partnership aims to provide safe and sustainable solutions for farmers in agricultural regions worldwide, and the agreement demonstrates the importance of innovation in sustainable technologies. Johnson & Johnson (JNJ) stock went up by 0.41% possibly due to a conference call scheduled for investors to review fourth-quarter results, where the company's leadership will discuss their healthcare innovation and impact on health for humanity.
	2023-12-08	-0.63 %
Johnson & Johnson (JNJ) stock went down by 0.63% last night, along with other competitors such as Procter & Gamble Co. (PG), with trading volume below its 50-day average volume.
	2023-12-07	-0.78 %
Johnson & Johnson (JNJ) stock went down because its consumer health division, Kenvue Inc., is facing a securities class action lawsuit for allegedly making misleading statements and omissions about the efficacy of its products, particularly phenylephrine, which led to significant losses for investors. The Johnson & Johnson (JNJ) stock went down by 0.78% last night, potentially due to a ruling by a New York judge regarding the use of Tylenol as a pain treatment for pregnant women. Johnson & Johnson (JNJ) stock went down by 0.78% due to factors not mentioned in the article.
	2023-12-06	-1.22 %
Johnson & Johnson (JNJ) stock went down by 1.22% last night, likely due to the broader market trend of modest losses and the decline in other healthcare giants' stock prices. Johnson & Johnson (JNJ) stock went down by 1.22% due to a securities class action lawsuit filed against Kenvue Inc. (formerly the consumer health division of Johnson & Johnson) alleging violations of federal securities laws and misleading statements about the efficacy of its products. Johnson & Johnson (JNJ) stock went down by 1.22% due to a rough overall trading session in the stock market, with the S&P 500 Index and Dow Jones Industrial Average also falling.
	2023-12-05	-0.21 %
The article summarizes a report by Synopsys, Inc. on the increasing adoption of automation in software security practices. The use of automated security technology is growing rapidly, which is leading to improved security processes throughout the software development life cycle. Johnson & Johnson's stock may have gone down for various reasons unrelated to the content of this article. The article discusses a healthcare conference held in Nashville that aimed to bring together leaders from different industries to find innovative solutions for the challenges in the healthcare sector. Key lessons learned from the conference include the importance of passion, discipline, and culture in driving success and improving patient care. However, the article does not mention anything about why Johnson & Johnson (JNJ) stock went down. Johnson & Johnson (JNJ) stock was slightly down last night, and the reason for the decline is not mentioned in the article.
	2023-12-04	+0.32 %
Johnson & Johnson (JNJ) stock went up because it is expected to continue growing its revenue and earnings in the coming years, driven by demand for its pharmaceuticals, medical devices, and consumer products according to Google Bard. Johnson & Johnson's (JNJ) stock increased by 0.32% as shares of Pfizer Inc. (PFE) rose 1.28% amidst a poor trading session, possibly due to positive market sentiment and investor confidence in the pharmaceutical industry. The article is not about Johnson & Johnson (JNJ) stock going up. It is about Alexandra Cooper, the podcast host of "Call Her Daddy," and her journey to success in the podcasting industry. The article discusses her athletic background, the success of her podcast, her contract controversy with Barstool Sports, her lucrative deal with Spotify, her personal life, real estate investments, and social media influence.
	2023-12-01	+2.41 %
The article is not about Johnson & Johnson (JNJ) stock; it is about a leadership addition at CNX Resources Corporation. Therefore, it does not explain why JNJ stock went up. Johnson & Johnson's stock increased by 2.41% after receiving a bullish recommendation due to positive prospects for the pharmaceutical and medical-device company. Johnson & Johnson's stock (JNJ) was up 2.41% last night, but the article does not provide a specific reason for the increase.
	2023-11-30	+1.68 %
Johnson & Johnson (JNJ) stock went up by 1.68% after the company announced the acquisition of Laminary, a medical device company, for $400 million, although it also revised its full-year profit outlook downward due to charges associated with the deal. Johnson & Johnson (JNJ) stock rose by 1.68% last night, and the article suggests that the stock went up due to potential innovation, despite concerns about inflation laws. Johnson & Johnson (JNJ) stock went up by 1.68% last night; however, the article does not provide any specific explanation for the increase in the stock price.
	2023-11-29	+0.32 %
Johnson & Johnson (JNJ) stock went up by 0.32% because the overall trading session was mixed, with the Dow Jones Industrial Average rising 0.04% and the S&P 500 Index falling 0.09%. Johnson & Johnson (JNJ) stock went up by 0.32% due to a mixed trading session, with the Dow Jones Industrial Average rising slightly and the S&P 500 Index falling slightly. Johnson & Johnson's stock (JNJ) went up by 0.32%, and the reason for the increase is not mentioned in the article.
	2023-11-28	+0.23 %
Johnson & Johnson (JNJ) stock went up by 0.23% last night. The reason for the increase in the stock price is not mentioned in the article. Johnson & Johnson (JNJ) stock went up by 0.23% last night. The article explains that blue-chip stocks like Johnson & Johnson are popular among investors due to their stability, long-term growth potential, and consistent performance. Johnson & Johnson's diversified business model across healthcare products, pharmaceuticals, medical devices, and consumer goods, as well as its history of consistent dividend payments and strong financial track record, make it attractive for investors seeking stability, innovation, and growth in the healthcare sector. The article discusses the recent performance of Alvotech, a biotech company specializing in biosimilar medicines, and its financial results for the first nine months of 2023. The article does not provide information specifically about Johnson & Johnson (JNJ) stock or why it has gone up.
	2023-11-27	-0.8 %
The article does not provide any information about Johnson & Johnson (JNJ) stock going down. Instead, it discusses Royalty Pharma's participation in a conference. The article discusses the popularity of investing in the S&P 500 index through ETFs and index funds, which provides diversification and exposure to the overall market. It also highlights the top stocks in the SPDR S&P 500 ETF Trust (SPY) based on their weighting in the fund, including Apple, Microsoft, Alphabet, Amazon, and Nvidia. The article does not mention why Johnson & Johnson (JNJ) stock went down. Johnson & Johnson (JNJ) stock went down by -0.8% last night, and according to an interview with Joseph Wolk, the Chief Financial Officer of Johnson & Johnson, the stock may have been impacted by concerns about inflation laws hampering innovation.
	2023-11-24	+1.11 %
Johnson & Johnson (JNJ) stock went up by 1.11% last night, but the article does not provide a specific reason for the increase. Johnson & Johnson (JNJ) stock rose 1.11% after the close, likely due to gains in the healthcare sector. The Johnson & Johnson (JNJ) stock went up by 1.11% last night, and the reason behind the increase is not mentioned in the article.
	2023-11-22	-0.2 %
The article discusses a class action lawsuit filed on behalf of investors who purchased Kenvue Inc. securities following the company's IPO in May 2023. The lawsuit alleges that the registration statement and prospectus issued in connection with the IPO contained false and misleading statements about the efficacy of the company's product, phenylephrine. After an FDA panel declared oral phenylephrine ineffective for relieving nasal congestion, Kenvue's stock declined, causing harm to investors. The lawsuit claims that the company failed to disclose these risks in its IPO, leading to misleading statements about its business and prospects. Johnson & Johnson's stock may have gone down due to its association with Kenvue and the negative news about the company's product. Warren Buffett's Berkshire Hathaway has sold all of its stock in Johnson & Johnson, among other American companies, which may have contributed to the -0.2% decrease in Johnson & Johnson's stock price. Johnson & Johnson (JNJ) stock went down because Berkshire Hathaway, led by Warren Buffett, completely sold off its long-time holdings in the company, along with other stocks such as Proctor and Gamble and Mondelez International.
	2023-11-21	+0.81 %
The article announces that a securities class action lawsuit has been filed against Kenvue Inc. for violations of federal securities laws, which has resulted in significant losses for investors, and provides information for investors to take action. The stock of Johnson & Johnson (JNJ) goes up because the article does not mention any direct correlation between the lawsuit against Kenvue Inc. and Johnson & Johnson (JNJ) stock performance. Johnson & Johnson (JNJ) stock went up by 0.81% last night, potentially due to its inclusion in GMO's quality stock-focused mutual funds, which seeks to select high-quality US stocks for above-average returns. The article discusses how Johnson & Johnson stock went up by 0.81% and explains that it is a popular choice for income investors.
	2023-11-20	+0.08 %
The article discusses the stock performance of Johnson & Johnson (JNJ), stating that it was up by 0.08% last night. However, the article does not provide a specific reason for the increase in JNJ stock.
	2023-11-17	-0.21 %
Johnson & Johnson (JNJ) stock went down by -0.21% last night, and the reason behind this decline is not mentioned in the article.
	2023-11-16	+0.87 %
Johnson & Johnson (JNJ) stock rose 0.87% last night, ending a two-day losing streak, and the reason for the increase is not mentioned in the article. Johnson & Johnson's stock went up by 0.87% due to mixed trading in the stock market, with its trading volume surpassing its 50-day average volume and its competitors, such as Medtronic PLC and Stryker Corp, also experiencing gains. Johnson & Johnson (JNJ) stock went up 0.87% last night, and the reason for the increase is not mentioned in the article.
	2023-11-15	+0.77 %
Johnson & Johnson (JNJ) stock went up by 0.77% last night, but the article does not provide a clear reason for this increase. The article reports that Johnson & Johnson (JNJ) stock went up by 0.77% last night, but it does not provide a reason for the increase. Johnson & Johnson (JNJ) stock went up by 0.77% last night. The reason for the increase is not mentioned in the article.
	2023-11-14	+0.02 %
Johnson & Johnson (JNJ) stock went up by 0.02% last night, likely influenced by the overall positive performance of the stock market and its competitors, Pfizer Inc. and Merck & Co. Inc. Johnson & Johnson (JNJ) stock went up by 0.02% due to hopes of a turnaround in the U.S. corporate bond market, as slowing U.S. inflation reduces the impact of the Federal Reserve's interest rate hikes on the bond prices of major companies. Johnson & Johnson (JNJ) stock went up by 0.02% due to a favorable trading session in the stock market.
	2023-11-13	+0.26 %
Johnson & Johnson (JNJ) stock went up by 0.26% last night. Moody's Investor Service has put the U.S. on alert for a possible downgrade of its triple-A sovereign rating due to higher interest rates and doubts about the government's ability to implement effective fiscal policies. Investors looking for AAA-rated U.S. debt have the option of investing in Johnson & Johnson or Microsoft. Moody's may not downgrade J&J and Microsoft unless they have changed their view on the companies' stand-alone fundamentals. J&J stock has lost 18% this year, while Microsoft stock is up 53% in the year to date. Royalty Pharma and Teva Pharmaceuticals have entered into a funding agreement of up to $125 million to accelerate the clinical research program for Teva's olanzapine LAI, a treatment for schizophrenia, which has caused Johnson & Johnson's (JNJ) stock to go up. Pfizer's stock is down due to declining demand for its Covid-19 products, resulting in a decrease in revenue and profits, while other pharmaceutical stocks, including Johnson & Johnson (JNJ), have also experienced declines. Despite this, pharmaceutical companies Eli Lilly and Novo Nordisk have seen their stocks rise due to the popularity of their weight loss medications. Johnson & Johnson's stock, in particular, is down nearly 20% from its 2021 high.
	2023-11-10	-0.12 %
The article mentions that Johnson & Johnson (JNJ) stock went down by 0.12% and the reason for the decline is not provided in the article. The article discusses Warren Buffett's recent sale of nearly $500 million in stocks, including Johnson & Johnson. It does not provide an explanation for why Johnson & Johnson's stock went down. The article reveals that Warren Buffett has held shares of Johnson & Johnson (JNJ) in his personal stock portfolio over the years and has recently sold $35 million worth of JNJ stock, potentially indicating that Berkshire Hathaway was also selling its stake in the company. The reason for the stock going down is not specified in the article.
	2023-11-09	-1.95 %
The article discusses how the U.S. stock market has recently shown positive market breadth, indicating a bullish sentiment, but Johnson & Johnson stock went down 1.95% last night. The reason for the decline in Johnson & Johnson stock is not specified in the article. Johnson & Johnson (JNJ) stock went down by 1.95% due to Warren Buffett's personal sale of $35 million worth of Johnson & Johnson shares, which contradicted Berkshire Hathaway's policy and raised questions about insider trading. Johnson & Johnson (JNJ) stock went down by -1.95% last night, but the article does not provide any explanation for why this happened.
	2023-11-08	-0.36 %
The article discusses the financial results and guidance of Royalty Pharma plc for the third quarter of 2023. The decline in Johnson & Johnson (JNJ) stock is not mentioned in the article, so it is unclear why it went down. Johnson & Johnson (JNJ) stock went down by -0.36% because Bayer Chief Executive Bill Anderson announced plans to overhaul Bayer's structure and reduce management layers, which resulted in significant job cuts. However, Anderson ruled out splitting the company into three businesses like other pharmaceutical companies have done. Johnson & Johnson (JNJ) stock went down by 0.36% due to a mixed trading session in the stock market, with the S&P 500 Index rising slightly and the Dow Jones Industrial Average falling slightly. The stock underperformed compared to some of its competitors.
	2023-11-07	-0.53 %
Johnson & Johnson's stock went down by 0.53% due to news that its MedTech unit plans to submit an application to the FDA in the second half of 2024 for clinical trials of its robotic surgical system, which would compete with market leaders like Intuitive Surgical's da Vinci robot. The article announces the appointment of Frederick Hrkac as Executive Vice President of BioSig Technologies, a medical technology company. The article does not provide any information about why Johnson & Johnson's stock went down. The article is not about Johnson & Johnson (JNJ) stock going down, but rather about Nanobiotix S.A. entering into an Underwriting Agreement for a Global Offering of its shares.
	2023-11-06	+0.24 %
Yesterday, Johnson & Johnson (JNJ) stock went up by 0.24%. The article does not provide a specific reason for why the stock went up. Johnson & Johnson (JNJ) stock went up 0.24% last night, but the article does not provide an explanation for the increase. Johnson & Johnson's stock went up by 0.24% because of the potential for advances in Alzheimer's and obesity treatments by Eli Lilly & Co., which is now the most valuable pharmaceutical company and a competitor to Johnson & Johnson.
	2023-11-03	+0.73 %
Johnson & Johnson (JNJ) stock went up by 0.73% due to a positive trading session for the overall stock market. Johnson & Johnson (JNJ) stock rose 0.73% last night, and the reason for the increase is not mentioned in the article. Johnson & Johnson (JNJ) stock went up by 0.73% last night, potentially driven by the launch of the Roundhill S&P Dividend Monarchs ETF, which includes JNJ as one of its top holdings and invests in US blue-chip companies that have consistently increased their dividends for at least five decades, appealing to investors looking for a recession-proof option.
	2023-11-02	+1.04 %
Johnson & Johnson's stock increased by 1.04% recently, and the reason for the increase is that weight-loss drugs could enable previously ineligible overweight patients to qualify for joint replacement surgery, potentially increasing demand for orthopaedic surgeries and offsetting lower demand for bariatric surgery. Biotechnology company Nanobiotix has announced the pricing of its global follow-on offering, consisting of an offering of American Depositary Shares (ADSs) in the US and ordinary shares in Europe, with proceeds expected to be approximately $55 million. Johnson & Johnson Innovation – JJDC, Inc. has agreed to subscribe for $25.0 million of ordinary shares in the form of restricted ADSs. The offering is expected to close on November 6. The article announces the pricing of Nanobiotix's global follow-on offering, which includes the offering of American Depositary Shares (ADSs) and ordinary shares, and Johnson & Johnson Innovation – JJDC, Inc. is obligated to subscribe for a certain amount of restricted ADSs in a concurrent private placement; the stock of Johnson & Johnson (JNJ) goes up because of this news.
	2023-11-01	+0.24 %
Johnson & Johnson (JNJ) stock went up by 0.24% last night. The article discusses a strategy of ranking and selecting stocks based on their expected returns and relative strength. The top five long recommendations for this month include Walmart, United Health, Intel, Merck, and Visa, while the top five short sale recommendations include Chevron, Goldman Sachs, Walgreen Boots, Johnson & Johnson, and Dow. The article mentions that United Health has historically performed well in November, while Chevron's technical picture is weak. It does not specifically mention why Johnson & Johnson's stock went up. The article announces the launch of a global follow-on offering by Nanobiotix, a biotechnology company, which includes Johnson & Johnson subscribing for $25.0 million of Ordinary Shares, and the stock goes up because of this news. Johnson & Johnson (JNJ) stock went up by 0.24% last night following the announcement of their acquisition of Industrial Vision Systems Ltd (IVS), a specialist in developing machine vision software and technology for high precision quality control systems used in various industries. This acquisition strengthens Oxford Metrics' strategy and allows them to provide cutting-edge machine vision solutions to well-known brands, resulting in faster and more reliable production processes.
	2023-10-31	+0.89 %
Johnson & Johnson (JNJ) stock went up by 0.89% and outperformed its competitors due to a positive trading session in the stock market. The article discusses the performance of Johnson & Johnson (JNJ) stock, which rose 0.89% last night compared to its competitors, Procter & Gamble Co. and Kimberly-Clark Corp. The reasons for the stock's increase are not mentioned in the article. Johnson & Johnson's stock increased by 0.89% due to positive market sentiment, along with its strong commitment to shareholder returns and solid financial health.
	2023-10-30	+0.98 %
The article announces the appointment of Jennifer Towne, Ph.D., as the Executive Vice President and Chief Scientific Officer of Vir Biotechnology, Inc. The stock of Johnson & Johnson went up, but the article does not provide a reason for this increase. The article announces that a class action lawsuit has been filed against Johnson & Johnson subsidiary Kenvue Inc. for allegedly failing to disclose concerns about the efficacy of its products, causing the price of Kenvue shares to decline. The stock of Johnson & Johnson (JNJ) went up by 0.98% last night.
	2023-10-27	-2.28 %
Johnson & Johnson (JNJ) stock went down by -2.28% last night due to concerns that the introduction of new weight-loss drugs, such as Novo Nordisk's Wegovy, could impact companies that profit from treating obesity-related health issues. Investors are apprehensive about the high prices of these weight-loss drugs, uncertainty over long-term usage, and potential lack of insurance coverage. This has led to a sell-off in companies that manufacture bariatric surgery devices and products addressing health issues caused by excess weight. Johnson & Johnson (JNJ) stock went down -2.28% due to the disclosure that the U.S. Department of Justice (DOJ) had launched a civil investigation into the company's free and discounted eye surgery products. Johnson & Johnson (JNJ) stock fell 2.28% due to a rough trading session in the stock market, with the S&P 500 and Dow Jones Industrial Average experiencing significant losses, and trading volume for JNJ surpassing its 50-day average volume.
	2023-10-26	-1.7 %
Johnson & Johnson (JNJ) stock went down by 1.7% last night, possibly due to a rough trading session for the overall stock market which saw the S&P 500 Index and Dow Jones Industrial Average fall. Johnson & Johnson (JNJ) stock went down by 1.7% due to a rough trading session in the stock market, with the S&P 500 Index falling by 1.18% and the Dow Jones Industrial Average falling by 0.76%. The stock underperformed compared to some of its competitors, including Bristol Myers Squibb, Pfizer Inc., and Abbott Laboratories. The trading volume for JNJ exceeded its 50-day average volume. Johnson & Johnson's stock went down by 1.7% due to a slowdown in demand for weight-loss and other procedures, as obese patients turned to rival drugs like Novo Nordisk's Wegovy and Ozempic. Companies across various sectors, including food and beverage makers and medical device makers, are facing investor concerns over the potential impact of these weight-loss treatments on their sales.
	2023-10-25	+0.22 %
Johnson & Johnson (JNJ) stock went up by 0.22% last night, but the article does not provide specific information on why the stock price increased. Johnson & Johnson's stock (JNJ) went up by 0.22% last night. The article does not provide a reason for the increase in the stock price. Johnson & Johnson's (JNJ) stock went up 0.22% last night, but the article does not provide any specific reasons for this increase as it focuses on the financial results and expectations of Alkermes plc.
	2023-10-24	-0.11 %
The article discusses how renowned investor Michael Burry has placed a bearish bet against the stock market by purchasing put options tied to major ETFs. This bet includes a bearish position against Johnson & Johnson (JNJ) stock, among other well-known companies. The article does not mention why Johnson & Johnson stock specifically went down last night. Johnson & Johnson (JNJ) stock went down by 0.11% due to underperformance compared to its competitors, Pfizer Inc. (PFE), Eli Lilly & Co. (LLY), and Abbott Laboratories (ABT), with trading volume below its average. Johnson & Johnson (JNJ) stock experienced a slight decline of -0.11% after reaching a 52-week low, despite the company reporting strong third-quarter financial results and raising its earnings forecast for the full year. The article does not provide a specific reason for the stock's decline.

1
500 / page